Transcript Association Between Use of Interferon Beta and Progression

From: Association Between Use of Interferon Beta and Progression of Disability in Patients With RelapsingRemitting Multiple Sclerosis
JAMA. 2012;308(3):247-256. doi:10.1001/jama.2012.7625
Figure Legend:
BCMS indicates British Columbia Multiple Sclerosis; DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; MS,
multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.aThe sum of the
individual reasons exceeds the total number of patients because some patients met more than 1 condition. bEight exposed to a
cytotoxic immunosupressant, 62 to glatiramer acetate, and 112 to interferon beta.
Date of download: 4/7/2017
Copyright © 2017 American Medical
Association. All rights reserved.
From: Association Between Use of Interferon Beta and Progression of Disability in Patients With RelapsingRemitting Multiple Sclerosis
JAMA. 2012;308(3):247-256. doi:10.1001/jama.2012.7625
Figure Legend:
EDSS indicates Expanded Disability Status Scale. Panel A shows findings when patient characteristics are considered potential
confounders. Covariates included in the model were sex, age at baseline, disease duration at baseline, EDSS score at baseline,
and interferon beta exposure as a time-varying covariate. Fifty-four patients who were censored before the earliest event did not
contribute to the analysis. Panel B shows findings when additional covariates (socioeconomic status [SES] and the Charlson
comorbidity index) were also considered. A further
68 patients
were
excluded
due to missing SES. Fifty-two patients who were
Copyright
© 2017
American
Medical
a2556.9 person-years (65 patients reached the outcome).
Date
of download:
4/7/2017
censored
before the
earliest event did not contribute
to
the
analysis.
Association. All rights reserved.
b4262.6 person-years (73 patients reached the outcome, 29 during the unexposed time in the interferon beta–treated cohort and 44
From: Association Between Use of Interferon Beta and Progression of Disability in Patients With RelapsingRemitting Multiple Sclerosis
JAMA. 2012;308(3):247-256. doi:10.1001/jama.2012.7625
Figure Legend:
EDSS indicates Expanded Disability Status Scale. Covariates included in the model were sex, age at baseline, disease duration at
baseline, EDSS score at baseline, and interferon beta exposure as a time-varying covariate. Twenty patients who were censored
before the earliest event did not contribute to the analysis. a2556.9 person-years (65 patients reached the outcome). b8921.3
person-years (251 patients reached the outcome, 29 during the unexposed time in the interferon beta–treated cohort and 222 in the
d1381 patients (231 reached the outcome, 67 in the interferon
historical control cohort). cEDSS at baseline ranged
from ©
0 to
6.5.American
Copyright
2017
Medical
e
Date
of
download:
4/7/2017
beta–treated cohort and 164 in the historical control
cohort). 446
patients
(85 reached the outcome, 27 in the interferon beta–
Association.
All rights
reserved.
treated cohort and 58 in the historical control cohort).